<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antidepressants, SSRI: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i232.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i232.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i232.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i229.htm">Antidepressants</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i231.htm" title="Previous: Reboxetine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i964.htm" title="Next: Escitalopram">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i232">Antidepressants, SSRI</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antidepressants, SSRI</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i20.htm" name="_20">Alcohol</a></td><td>sedative effects possibly increased when  SSRIs given with alcohol </td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b> SSRIs increase plasma concentration of some tricyclics </b></td><td></td></tr><tr><td><a href="41001i276.htm" name="_276">Antiepileptics</a></td><td class="cBV"><b> SSRIs antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i361.htm">Aspirin</a></td><td class="cBV"><b>increased risk of bleeding when  SSRIs given with aspirin </b></td><td></td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> SSRIs possibly enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i317.htm">Cyproheptadine</a></td><td>antidepressant effect of  SSRIs possibly antagonised by cyproheptadine </td><td></td></tr><tr><td><a href="41001i1024.htm" name="_1024">Duloxetine</a></td><td>possible increased serotonergic effects when  SSRIs given with duloxetine </td><td></td></tr><tr><td><a href="41001i372.htm" name="_372">Lithium</a></td><td class="cBV"><b>Increased risk of CNS effects when  SSRIs given with lithium (lithium toxicity reported)</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>CNS effects of  SSRIs increased by MAOIs (risk of serious toxicity)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>metabolism of  SSRIs possibly inhibited by methylphenidate </td><td></td></tr><tr><td><a href="41001i613.htm" name="_613">Metoclopramide</a></td><td>CNS toxicity reported when  SSRIs given with metoclopramide </td><td></td></tr><tr><td><a href="41001i573.htm" name="_573">Naratriptan</a></td><td>possible increased serotonergic effects when  SSRIs given with naratriptan </td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>increased risk of bleeding when  SSRIs given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b> SSRIs possibly increase plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>increased risk of CNS toxicity when  SSRIs given with rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  SSRIs possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>increased serotonergic effects when  SSRIs given with St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td class="cBV"><b>increased risk of CNS toxicity when  SSRIs given with tramadol </b></td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td class="cBV"><b>agitation and nausea may occur when  SSRIs given with tryptophan </b></td><td></td></tr></tbody></table><p>Antidepressants, SSRI belongs to <b>Antidepressants</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  antidepressants advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td>possible increased risk of convulsions when  antidepressants given with atomoxetine </td><td></td></tr></tbody></table><p><b>Escitalopram</b> belongs to
      <b>Antidepressants, SSRI</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  escitalopram increased by cimetidine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> escitalopram should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping escitalopram</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> escitalopram increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>increased risk of CNS toxicity when  escitalopram given with moclobemide , preferably avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of  escitalopram increased by omeprazole </td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>avoidance of  escitalopram advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  escitalopram given with sumatriptan </b></td><td></td></tr></tbody></table><p><b>Citalopram</b> belongs to
      <b>Antidepressants, SSRI</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i572.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td class="cBV"><b>increased risk of CNS toxicity when  citalopram given with 5HT<sub>1</sub> agonists (manufacturer of citalopram advises avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td>plasma concentration of  citalopram possibly increased by bupropion </td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  citalopram increased by cimetidine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> citalopram possibly increases plasma concentration of clozapine (increased risk of toxicity)</td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> citalopram should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping citalopram</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> citalopram increases plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  citalopram do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>avoidance of  citalopram advised by manufacturer of selegiline </td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  citalopram given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>possible increased risk of bleeding when  citalopram given with ticagrelor </td><td></td></tr></tbody></table><p><b>Fluoxetine</b> belongs to
      <b>Antidepressants, SSRI</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





















<tr><td><a href="41001i406.htm">Alprazolam</a></td><td> fluoxetine increases plasma concentration of alprazolam </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> fluoxetine possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td> fluoxetine possibly inhibits metabolism of atomoxetine </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> fluoxetine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  fluoxetine advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td> fluoxetine increases plasma concentration of flecainide </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of haloperidol </b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> fluoxetine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 5 weeks after stopping fluoxetine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> fluoxetine possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  fluoxetine given with mirtazapine </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  fluoxetine do not start moclobemide for 5 weeks</b></td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td> fluoxetine possibly inhibits metabolism of nifedipine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> fluoxetine increases plasma concentration of phenytoin </b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b> fluoxetine should not be started until 2 weeks after stopping rasagiline , also rasagiline should not be started until at least 5 weeks after stopping fluoxetine</b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i368.htm">Risperidone</a></td><td> fluoxetine increases plasma concentration of risperidone </td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  fluoxetine given with selegiline (selegiline should not be started until 5 weeks after stopping fluoxetine, avoid fluoxetine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  fluoxetine given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td class="cBV"><b> fluoxetine possibly inhibits metabolism of tamoxifen to active metabolite (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i263.htm">Tryptophan</a></td><td>CNS toxicity reported when  fluoxetine given with tryptophan </td><td></td></tr></tbody></table><p><b>Fluvoxamine</b> belongs to
      <b>Antidepressants, SSRI</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i1145.htm">Agomelatine</a></td><td class="cBV"><b> fluvoxamine inhibits metabolism of agomelatine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1209.htm">Asenapine</a></td><td> fluvoxamine possibly increases plasma concentration of asenapine </td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td> fluvoxamine increases plasma concentration of some benzodiazepines </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> fluvoxamine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  fluvoxamine advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td class="cBV"><b> fluvoxamine inhibits metabolism of duloxetine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i965.htm">Frovatriptan</a></td><td> fluvoxamine inhibits the metabolism of frovatriptan </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> fluvoxamine possibly increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td> fluvoxamine possibly increases plasma concentration of lansoprazole </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> fluvoxamine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping fluvoxamine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i1114.htm">Melatonin</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of melatonin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> fluvoxamine possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>possible increased serotonergic effects when  fluvoxamine given with mirtazapine </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  fluvoxamine do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i366.htm">Olanzapine</a></td><td> fluvoxamine increases plasma concentration of olanzapine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of phenytoin </b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> fluvoxamine increases plasma concentration of propranolol </td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b> fluvoxamine should not be started until 2 weeks after stopping rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>avoidance of  fluvoxamine advised by manufacturer of reboxetine </b></td><td></td></tr><tr><td><a href="41001i1190.htm">Roflumilast</a></td><td> fluvoxamine inhibits the metabolism of roflumilast </td><td></td></tr><tr><td><a href="41001i888.htm">Ropivacaine</a></td><td> fluvoxamine inhibits metabolism of ropivacaine—avoid prolonged administration of ropivacaine</td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  fluvoxamine given with selegiline (selegiline should not be started until 1 week after stopping fluvoxamine, avoid fluvoxamine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  fluvoxamine given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of theophylline (concomitant use should usually be avoided, but where not possible halve theophylline dose and monitor plasma-theophylline concentration)</b></td><td></td></tr><tr><td><a href="41001i805.htm">Tizanidine</a></td><td class="cBV"><b> fluvoxamine increases plasma concentration of tizanidine (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td> fluvoxamine possibly inhibits metabolism of zolmitriptan (reduce dose of zolmitriptan)</td><td></td></tr></tbody></table><p><b>Paroxetine</b> belongs to
      <b>Antidepressants, SSRI</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>























<tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> paroxetine possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i1209.htm">Asenapine</a></td><td>plasma concentration of  paroxetine possibly increased by asenapine </td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td> paroxetine possibly inhibits metabolism of atomoxetine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> paroxetine increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td> paroxetine increases plasma concentration of darifenacin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of  paroxetine possibly reduced by darunavir </td><td></td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td> paroxetine increases plasma concentration of galantamine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> paroxetine should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping paroxetine</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> paroxetine possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> paroxetine possibly increases plasma concentration of metoprolol (enhanced effect)</td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  paroxetine do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i381.htm">Perphenazine</a></td><td> paroxetine inhibits metabolism of perphenazine (reduce dose of perphenazine)</td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  paroxetine reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  paroxetine reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i354.htm">Procyclidine</a></td><td> paroxetine increases plasma concentration of procyclidine </td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td> paroxetine possibly inhibits metabolism of propafenone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td> paroxetine increases plasma concentration of ranolazine </td><td></td></tr><tr><td><a href="41001i368.htm">Risperidone</a></td><td> paroxetine possibly increases plasma concentration of risperidone (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  paroxetine possibly reduced by ritonavir </td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  paroxetine given with selegiline (selegiline should not be started until 2 weeks after stopping paroxetine, avoid paroxetine for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td class="cBV"><b>increased risk of CNS toxicity when  paroxetine given with sumatriptan </b></td><td></td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td class="cBV"><b> paroxetine possibly inhibits metabolism of tamoxifen to active metabolite (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>possible increased risk of bleeding when  paroxetine given with ticagrelor </td><td></td></tr></tbody></table><p><b>Sertraline</b> belongs to
      <b>Antidepressants, SSRI</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>













<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  sertraline increased by cimetidine </td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> sertraline increases plasma concentration of clozapine </b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of  sertraline possibly reduced by darunavir </td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  sertraline advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  sertraline possibly increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b> sertraline should not be started until 2 weeks after stopping MAOIs , also MAOIs should not be started until at least 1 week after stopping sertraline</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> sertraline possibly increases plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  sertraline do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  sertraline possibly reduced by phenytoin , also plasma concentration of phenytoin possibly increased</td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  sertraline given with selegiline (selegiline should not be started until 1 week after stopping sertraline, avoid sertraline for 2 weeks after stopping selegiline)</b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i574.htm">Sumatriptan</a></td><td>CNS toxicity reported when  sertraline given with sumatriptan </td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td>possible increased risk of bleeding when  sertraline given with ticagrelor </td><td></td></tr><tr><td><a href="41001i425.htm">Zolpidem</a></td><td>sedative effects possibly increased when  sertraline given with zolpidem </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i964.htm" title="Escitalopram">Escitalopram</a></li><li><a href="41001i233.htm" title="Citalopram">Citalopram</a></li><li><a href="41001i234.htm" title="Fluoxetine">Fluoxetine</a></li><li><a href="41001i235.htm" title="Fluvoxamine">Fluvoxamine</a></li><li><a href="41001i236.htm" title="Paroxetine">Paroxetine</a></li><li><a href="41001i237.htm" title="Sertraline">Sertraline</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i231.htm">Previous: Reboxetine</a> | <a class="top" href="41001i232.htm#">Top</a> | <a accesskey="]" href="41001i964.htm">Next: Escitalopram</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>